Latest Period
Q4 2025
Security Snapshot
Cullinan Therapeutics, Inc. - Common Stock (CGEM) Institutional Ownership
CUSIP: 230031106
13F Institutional Holders and Ownership History from Q1 2021 to Q1 2026
Institutions Reporting
152
Shares (Excl. Options)
63,191,497
Price
$10.35
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Type / Class
- Equity / Common Stock
- Symbol
- CGEM on Nasdaq
- Shares outstanding
- 59,091,689
- Price per share
- $14.25
- All holders as of 31 Dec 2025
- Q4 2025
- Total 13F shares
- 63,191,497
- Total reported value
- $653,881,687
- % of total 13F portfolios
- 0%
- Share change
- +1,996,525
- Value change
- +$34,293,716
- Number of holders
- 152
- Price from insider filings
- $14.25
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Quick Takeaways
- CGEM - Cullinan Therapeutics, Inc. - Common Stock is tracked under CUSIP 230031106.
- 152 institutions reported positions in Q4 2025.
- 6 significant owners is listed from Schedule 13D/13G reporting.
What Changed
- Holder count moved from 152 to 40 between Q4 2025 and Q1 2026.
- Reported value moved from $653,881,687 to $169,429,230.
Why This Matters
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Source Evidence
Source: SEC Form 13F
Open SEC Evidence
Latest holder context comes from 152 institutions filings for Q4 2025.
Investment Quick Answers
What is CUSIP 230031106?
CUSIP 230031106 identifies CGEM - Cullinan Therapeutics, Inc. - Common Stock in SEC 13F datasets.
Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.
Next ownership checks
Use the next link that matches the question you still need to answer about this security.
- Latest 13F filings when you want to inspect fresh institutional portfolio moves.
- Latest Schedule 13D/13G reports when you need large-owner changes outside the 13F cycle.
- All institutional ownership pages to compare this security with other holder-history pages.
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 230031106:
Significant Owners of Cullinan Therapeutics, Inc. - Common Stock (CGEM) based on Schedule 13D/G filings
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Lynx1 Capital Management LP | 14% | +100% | $50,697,778 | +$24,599,905 | 8,549,084 | +94% | Lynx1 Capital Management LP | 08 Oct 2025 |
| BIOTECHNOLOGY VALUE FUND L P | 10% | $64,748,182 | 5,918,481 | BVF PARTNERS L P/IL | 31 Dec 2025 | |||
| Kynam Capital Management, LP | 5.3% | $37,245,019 | 3,114,132 | Kynam Capital Management, LP | 31 Dec 2025 | |||
| Flynn James E | 5% | $17,357,187 | 2,927,013 | Deerfield Mgmt, L.P. | 30 Sep 2025 | |||
| FRANKLIN RESOURCES INC | 3.8% | $17,836,873 | 2,191,262 | Franklin Resources, Inc. | 30 Sep 2024 | |||
| CITADEL ADVISORS LLC | 3.4% | -34% | $11,794,219 | -$6,049,899 | 1,988,907 | -34% | Kenneth Griffin | 30 Sep 2025 |
As of 31 Dec 2025, 152 institutional investors reported holding 63,191,497 shares of Cullinan Therapeutics, Inc. - Common Stock (CGEM). This represents 107% of the company’s total 59,091,689 outstanding shares.
Top 25 Institutional Shareholders
The largest institutional shareholders of Cullinan Therapeutics, Inc. - Common Stock (CGEM) together control 91% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| Lynx1 Capital Management LP | 15% | 8,963,500 | +55% | 19% | $92,772,225 |
| MPM BIOIMPACT LLC | 13% | 7,648,268 | 0% | 9.1% | $79,159,574 |
| BVF INC/IL | 9.7% | 5,750,683 | 0% | 2% | $59,519,569 |
| BlackRock, Inc. | 7.4% | 4,400,296 | +5.5% | 0% | $45,543,064 |
| VANGUARD GROUP INC | 5.6% | 3,298,504 | +12% | 0% | $34,139,516 |
| Kynam Capital Management, LP | 5.3% | 3,114,132 | +35% | 2.1% | $32,231,266 |
| Blue Owl Capital Holdings LP | 4% | 2,350,972 | -6.4% | 7.5% | $24,332,560 |
| STATE STREET CORP | 3.7% | 2,197,338 | +31% | 0% | $22,742,448 |
| Affinity Asset Advisors, LLC | 3.3% | 1,932,106 | +632% | 1.4% | $19,997,297 |
| RTW INVESTMENTS, LP | 2.9% | 1,705,960 | 0% | 0.18% | $17,656,686 |
| VR ADVISER, LLC | 2.3% | 1,379,965 | 0% | 0.71% | $14,282,638 |
| GEODE CAPITAL MANAGEMENT, LLC | 2.2% | 1,302,262 | +0.54% | 0% | $13,481,334 |
| BOOTHBAY FUND MANAGEMENT, LLC | 2.1% | 1,237,043 | 0.34% | $12,803,395 | |
| Siren, L.L.C. | 2% | 1,193,410 | 0% | 0.37% | $12,351,794 |
| Nextech Invest, Ltd. | 1.9% | 1,141,145 | 0% | 1.1% | $11,810,851 |
| DIMENSIONAL FUND ADVISORS LP | 1.4% | 848,769 | -28% | 0% | $8,783,184 |
| MORGAN STANLEY | 1.3% | 766,934 | +92% | 0% | $7,937,772 |
| GOLDMAN SACHS GROUP INC | 1.2% | 721,864 | -27% | 0% | $7,471,292 |
| GREAT POINT PARTNERS LLC | 1.1% | 634,032 | 2.1% | $6,562,231 | |
| RENAISSANCE TECHNOLOGIES LLC | 1.1% | 631,706 | +19% | 0.01% | $6,538,157 |
| TWIN FOCUS CAPITAL PARTNERS, LLC | 1% | 595,489 | 0% | 0.71% | $6,163,311 |
| DEUTSCHE BANK AG\ | 0.99% | 586,636 | +2.6% | 0% | $6,071,683 |
| Nuveen, LLC | 0.98% | 579,095 | +169% | 0% | $5,993,634 |
| TWO SIGMA INVESTMENTS, LP | 0.8% | 470,526 | +689% | 0.01% | $4,869,944 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 0.74% | 436,273 | +8.4% | 0% | $4,515,426 |
Institutional Holders of Cullinan Therapeutics, Inc. - Common Stock (CGEM) across Reporting Periods
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 11,923,547 | $169,429,230 | +$1,446,372 | $14.21 | 40 |
| 2025 Q4 | 63,191,497 | $653,881,687 | +$34,293,716 | $10.35 | 152 |
| 2025 Q3 | 61,075,479 | $362,176,403 | -$12,503,675 | $5.93 | 142 |
| 2025 Q2 | 62,610,123 | $471,432,056 | -$15,598,491 | $7.53 | 141 |
| 2025 Q1 | 64,669,430 | $489,559,204 | -$25,799,469 | $7.57 | 145 |
| 2024 Q4 | 65,580,571 | $798,774,691 | -$43,310,126 | $12.18 | 144 |
| 2024 Q3 | 65,000,732 | $1,087,002,831 | -$1,185,148 | $16.74 | 136 |
| 2024 Q2 | 62,920,773 | $1,097,340,923 | +$411,767,308 | $17.44 | 134 |
| 2024 Q1 | 39,359,979 | $670,698,022 | +$49,224,262 | $17.04 | 113 |
| 2023 Q4 | 36,858,851 | $375,589,972 | +$26,958,804 | $10.19 | 110 |
| 2023 Q3 | 38,010,712 | $344,003,620 | +$11,040,871 | $9.05 | 104 |
| 2023 Q2 | 36,693,312 | $394,818,289 | +$48,696,476 | $10.76 | 102 |
| 2023 Q1 | 32,209,329 | $329,495,842 | -$56,320,751 | $10.23 | 97 |
| 2022 Q4 | 37,711,425 | $397,852,399 | +$5,318,094 | $10.55 | 94 |
| 2022 Q3 | 37,032,227 | $474,756,845 | -$7,043,826 | $12.82 | 94 |
| 2022 Q2 | 37,570,810 | $481,656,895 | +$20,400,666 | $12.82 | 81 |
| 2022 Q1 | 36,763,865 | $384,914,646 | +$4,824,538 | $10.47 | 77 |
| 2021 Q4 | 36,386,962 | $559,714,828 | +$6,266,769 | $15.43 | 74 |
| 2021 Q3 | 33,862,280 | $762,265,836 | +$33,803,888 | $22.57 | 63 |
| 2021 Q2 | 32,250,659 | $828,539,736 | -$17,650,444 | $25.75 | 70 |
| 2021 Q1 | 31,323,171 | $1,298,948,827 | +$1,298,948,827 | $41.67 | 70 |